Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy Jun 12, 2023
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules May 23, 2023
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 22, 2023
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023 May 19, 2023
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 15, 2023
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 15, 2023
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 12, 2023
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 12, 2023
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy May 11, 2023
